Prøve GULL - Gratis
Why Holomedicine Is Rapidly Gaining Ground
BioSpectrum Asia
|BioSpectrum Asia April 2022
Medical holography has emerged as one of the most promising applications in the medical industry. Holographic imaging technology is advancing healthcare, life sciences, biomedical research as well as medical training and education. Mixed Reality (MR) applications are gradually making a progressive impact on healthcare deliveries with precise quantitative measurement of human internal anatomy elements in 3D holograms geometries displayed in actual physical space. Holographic 3D technology renders medical professionals with advanced diagnostic capabilities and surgical planning, by allowing them to slice virtual tissue, organs, and other body parts at various angles. Holomedicne advances access to percutaneous procedures without invasive needle techniques. Surgeons across the world are now curious to explore medical holograms to enhance the efficiency of complex surgeries.
Typically, conventional 3D (3-Dimensional) imaging technologies are not able to create a truly accurate 3D rendition. Actually, these are 2D images gathered from MRI, CT scanner, ultrasound, and other devices, stitched together to create a rough 3D image. Furthermore, it is extremely laborious and time-consuming to create 3D visualisations from these 2D images. Treatment and diagnostic decisions based on these images are rather challenging, plus their accuracy is often questionable. As a solution to these challenges, novel revolutionary medical holography technology renders 2D images into 3D floating projections applying Mixed Reality (MR), a blend of physical and digital worlds, which unlocks natural and intuitive holograms through 3D interactions.
In contrast to AR/VR, in MR the real environment remains visible at all times and the holograms appear in the real space passing through a holographic device. This enables medical professionals to zoom in and zoom out the magnified 3D hologram of an organ/tissue under study. These visuals are indistinguishable in a conventional scanning procedure and thus holograms make treatments and surgeries a seamless effort with live explicit interactions.
Trends and opportunities in the medical holography market:
The clinical application of holography is thriving with the rising adoption of health-tech products in the life science and healthcare sector. The holography products can range from holography displays, holography microscopes, holography prints, holography software and devices, holographic headsets, and holoscopes.
Denne historien er fra BioSpectrum Asia April 2022-utgaven av BioSpectrum Asia.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA BioSpectrum Asia
BioSpectrum Asia
India signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.
1 min
BioSpectrum Asia Oct 2025
BioSpectrum Asia
New Zealand to lead new gene therapy trial for muscular dystrophy
The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.
1 min
BioSpectrum Asia Oct 2025
BioSpectrum Asia
Scientists in Australia grow living skin in world-first
Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.
1 min
BioSpectrum Asia Oct 2025
BioSpectrum Asia
India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare
HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.
1 min
BioSpectrum Asia Oct 2025
BioSpectrum Asia
TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund
Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).
1 min
BioSpectrum Asia Oct 2025
BioSpectrum Asia
National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan
Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).
1 min
BioSpectrum Asia Oct 2025
BioSpectrum Asia
Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium
Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.
1 min
BioSpectrum Asia Oct 2025
BioSpectrum Asia
Korea makes smart patch that can run tests using sweat instead of blood
A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.
1 min
BioSpectrum Asia Oct 2025
BioSpectrum Asia
ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka
The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.
1 min
BioSpectrum Asia Oct 2025
BioSpectrum Asia
Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines
China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.
1 min
BioSpectrum Asia Oct 2025
Translate
Change font size
